Mediwound Ltd
MDWD18.400USD
-0.130-0.70%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
207.03MCap. mercado
PérdidaP/E TTM
Más Datos de Mediwound Ltd Compañía
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Información de la empresa
Símbolo de cotizaciónMDWD
Nombre de la empresaMediwound Ltd
Fecha de salida a bolsaMar 20, 2014
Director ejecutivoMr. Ofer Gonen
Número de empleados111
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 20
Dirección42 Hayarkon Street
CiudadYAVNE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísIsrael
Código postal8122745
Teléfono972779714100
Sitio Webhttps://www.mediwound.com/
Símbolo de cotizaciónMDWD
Fecha de salida a bolsaMar 20, 2014
Director ejecutivoMr. Ofer Gonen
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Dr. Shmulik Hess
Dr. Shmulik Hess
Chief Operating Officer, Chief Commercial Officer
Chief Operating Officer, Chief Commercial Officer
--
--
Dr. Robert J. Snyder
Dr. Robert J. Snyder
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
USA
15.46M
76.47%
EU and other international markets
4.76M
23.53%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Clal Biotechnology Industries Ltd
13.71%
Investor AB
8.07%
Yelin Lapidot Provident Funds Management Ltd
7.94%
Rosalind Advisors, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.02%
Other
61.58%
Accionistas
Accionistas
Proporción
Clal Biotechnology Industries Ltd
13.71%
Investor AB
8.07%
Yelin Lapidot Provident Funds Management Ltd
7.94%
Rosalind Advisors, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.02%
Other
61.58%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
20.44%
Holding Company
13.71%
Private Equity
8.07%
Hedge Fund
6.43%
Investment Advisor/Hedge Fund
4.48%
Venture Capital
3.50%
Corporation
2.57%
Individual Investor
1.68%
Research Firm
0.59%
Other
38.51%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
127
6.76M
62.53%
-1.01M
2025Q1
129
6.76M
62.72%
-1.01M
2024Q4
118
7.26M
67.33%
+161.02K
2024Q3
115
7.34M
70.49%
+440.76K
2024Q2
91
5.75M
66.40%
+288.97K
2024Q1
69
5.35M
61.63%
-376.56K
2023Q4
61
5.55M
64.63%
+32.10K
2023Q3
62
5.26M
71.22%
+1.01M
2023Q2
64
5.23M
72.67%
+954.42K
2023Q1
68
5.13M
65.71%
+1.13M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Clal Biotechnology Industries Ltd
1.48M
13.71%
--
--
Mar 15, 2025
Investor AB
872.09K
8.07%
--
--
Mar 31, 2025
Yelin Lapidot Provident Funds Management Ltd
858.00K
7.94%
+6.64K
+0.78%
Mar 31, 2025
Rosalind Advisors, Inc.
506.89K
4.69%
-121.16K
-19.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
434.00K
4.02%
+34.17K
+8.55%
Mar 31, 2025
Israel Biotech Fund
378.62K
3.5%
-172.63K
-31.32%
Mar 15, 2025
Deep Insight Limited Partnership
278.18K
2.57%
-273.07K
-49.54%
Mar 15, 2025
Gonen (Ofer)
182.10K
1.68%
+83.37K
+84.44%
Mar 15, 2025
T. Rowe Price Associates, Inc.
154.95K
1.43%
+150.56K
+3429.70%
Mar 31, 2025
Essex Investment Management Company, LLC
147.87K
1.37%
-1.08K
-0.73%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ARK Israel Innovative Technology ETF
1.58%
Invesco NASDAQ Future Gen 200 ETF
0.4%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ARK Israel Innovative Technology ETF
Proporción1.58%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.4%
iShares Micro-Cap ETF
Proporción0.03%
iShares Russell 2000 Growth ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Fecha
Tipo
Relación
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
